✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals

Ajanta Pharma Ltd.

AJANTPHARM

Market Cap
₹39,703 Cr.
P/E
37.60

Ajanta Pharma Ltd.

  • Ajanta Pharma
  • Glaxosmithkline Phar
  • Ipca Laboratories
  • TJI Pharma

FAQs on Ajanta Pharma Ltd. Shareprice

Ajanta Pharma has given better returns compared to its competitors.
Ajanta Pharma has grown at ~18.9% over the last 5yrs while peers have grown at a median rate of 11.34%

Yes, Ajanta Pharma is expensive.
Latest PE of Ajanta Pharma is 37.6, while 3 year average PE is 32.53.
Also latest EV/EBITDA of Ajanta Pharma is 28.54 while 3yr average is 24.16.

View FAQ's On Business

Growth Table

  • Ajanta Pharma Ltd.
  • Glaxosmithkline Phar
  • Ipca Laboratories

Balance Sheet

  • Ajanta Pharma Ltd.
  • Glaxosmithkline Phar
  • Ipca Laboratories

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Ajanta Pharma Ltd.
  • Glaxosmithkline Phar
  • Ipca Laboratories

Cash Flow

  • Ajanta Pharma Ltd.
  • Glaxosmithkline Phar
  • Ipca Laboratories

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Ajanta Pharma Ltd.
  • Glaxosmithkline Phar
  • Ipca Laboratories

Quarterly Results

  • Ajanta Pharma Ltd.
  • Glaxosmithkline Phar
  • Ipca Laboratories

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Ajanta Pharma Ltd. Financials

Balance sheet of Ajanta Pharma is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Ajanta Pharma is increasing.
Latest net debt of Ajanta Pharma is ₹2.46 Crs as of Mar-26.
This is greater than Mar-25 when it was -₹349.89 Crs.

Yes, profit is increasing.
The profit of Ajanta Pharma is ₹1,056 Crs for Mar 2026, ₹920 Crs for Mar 2025 and ₹816 Crs for Mar 2024

The company seems to pay a good stable dividend.
Ajanta Pharma latest dividend payout ratio is 33.12% and 3yr average dividend payout ratio is 49.93%

Companies resources are allocated to majorly unproductive assets like Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech